ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

GlaxoSmithKline, Gilead Sciences and Pfizer side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

GlaxoSmithKline×Gilead Sciences×Pfizer×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

GlaxoSmithKlineGilead SciencesPfizer
studies on the registry4,1987394,073
open to participants now13633147
phase 3 studies under way783399
reach primary completion within a year681992
programswith a study of their own in two years88+17 named only3291+9 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGlaxoSmithKlineGilead SciencesPfizer
Phase 1

GlaxoSmithKline: 19 of its 88 programs at phase 1

  1. Pn-MAPS30plusphase 1
  2. GSK4771261phase 1
  3. Antibody-drug Conjugate GSK5533524phase 1
  4. ganfeborolephase 1
  5. GSK4425689Aphase 1

and 14 more — sign in to see them all

22%

Gilead Sciences: 6 of its 32 programs at phase 1

  1. GS-0151phase 1
  2. GS-0415phase 1
  3. GS-1206phase 1
  4. GS-2426phase 1
  5. GS-5319phase 1

and 1 more — sign in to see them all

19%

Pfizer: 42 of its 91 programs at phase 1

  1. polfurmetinibphase 1
  2. claturafenibphase 1
  3. PF-07985631phase 1
  4. PF-08642534phase 1
  5. Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876phase 1

and 37 more — sign in to see them all

46%
Phase 2

GlaxoSmithKline: 36 of its 88 programs at phase 2

  1. dezecapavirphase 2
  2. nelistotugphase 2
  3. GSK3862995Bphase 2
  4. VH4524184phase 2
  5. nirogacestatphase 2

and 31 more — sign in to see them all

41%

Gilead Sciences: 6 of its 32 programs at phase 2

  1. Autologous Anti-CD19/CD20 CAR-T Cells KITE-363phase 2
  2. denikitugphase 2
  3. GS-1179phase 2
  4. GS-4321phase 2
  5. PTM Cilofexor Dose Aphase 2

and 1 more — sign in to see them all

19%

Pfizer: 10 of its 91 programs at phase 2

  1. PF-07328948phase 2
  2. tegtociclibphase 2
  3. PF-08653945phase 2
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 5 more — sign in to see them all

11%
Phase 3

GlaxoSmithKline: 23 of its 88 programs at phase 3

  1. belantamab mafodotinphase 3
  2. felcorekibartphase 3
  3. risvutatug rezetecanphase 3
  4. velzatinibphase 3
  5. efimosfermin alfaphase 3

and 18 more — sign in to see them all

26%

Gilead Sciences: 15 of its 32 programs at phase 3

  1. anitocabtagene autoleucelphase 3
  2. domvanalimabphase 3
  3. seladelparphase 3
  4. axicabtagene ciloleucelphase 3
  5. GS-3242phase 3

and 10 more — sign in to see them all

47%

Pfizer: 31 of its 91 programs at phase 3

  1. berobenatidephase 3
  2. tivunatamigphase 3
  3. tilrekimigphase 3
  4. ritlecitinibphase 3
  5. abrysvophase 3

and 26 more — sign in to see them all

34%
Approved, new studies

GlaxoSmithKline: 10 of its 88 programs at approved, new studies

  1. dostarlimabapproved, new study
  2. cabotegravirapproved, new study
  3. depemokimabapproved, new study
  4. belimumabapproved, new study
  5. niraparibapproved, new study

and 5 more — sign in to see them all

11%

Gilead Sciences: 5 of its 32 programs at approved, new studies

  1. sacituzumab govitecanapproved, new study
  2. lenacapavirapproved, new study
  3. tenofovir alafenamideapproved, new study
  4. bictegravirapproved, new study
  5. Emtricitabineapproved, new study
16%

Pfizer: 8 of its 91 programs at approved, new studies

  1. rimegepantapproved, new study
  2. tucatinibapproved, new study
  3. elranatamabapproved, new study
  4. tisotumab vedotinapproved, new study
  5. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineapproved, new study

and 3 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
GlaxoSmithKline40 readouts · 8 phase 3

GlaxoSmithKline, Nov ’26: 4 programs whose next study reaches primary completion, 2 in phase 3

  1. Pn-MAPS30plusphase 1 · Nov 19 · NCT07428759
  2. dostarlimabapproved, new study · Nov 23 · NCT06567782
  3. Pentetic Acidphase 3 · Nov 23 · NCT07596199
  4. niraparibapproved, new study · Nov 26 · NCT03981796

GlaxoSmithKline, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccinephase 1 · Dec 3 · NCT07464314
  2. momelotinibphase 3 · Dec 11 · NCT03441113
  3. GSK3862995Bphase 2 · Dec 16 · NCT06154837
  4. HFA-152aphase 3 · Dec 28 · NCT07645248
  5. norfluranephase 3 · Dec 28 · NCT07645248

and 1 more — sign in to see them all

GlaxoSmithKline, Jan ’27: 4 programs whose next study reaches primary completion

  1. Adjuvanted RSVPreF3 vaccinephase 2 · Jan 12 · NCT07092865
  2. velzatinibphase 3 · Jan 12 · NCT07862114
  3. SOC INSTI-based ARTphase 1 · Jan 22 · NCT07053384
  4. VH3810109phase 2 · Jan 22 · NCT07053384

GlaxoSmithKline, Feb ’27: 1 program whose next study reaches primary completion

  1. dezecapavirphase 2 · Feb 18 · NCT07934719

GlaxoSmithKline, Mar ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. depemokimabapproved, new study · Mar 1 · NCT07671001
  2. CAB ULAphase 3 · Mar 8 · NCT06786520
  3. cabotegravirapproved, new study · Mar 8 · NCT06786520
  4. camlipixantphase 3 · Mar 9 · NCT07519395
  5. ozureprubartphase 2 · Mar 16 · NCT07220811

and 1 more — sign in to see them all

GlaxoSmithKline, Apr ’27: 2 programs whose next study reaches primary completion

  1. felcorekibartphase 3 · Apr 13 · NCT07712393
  2. as01ephase 2 · Apr 23 · NCT07036159

GlaxoSmithKline, May ’27: 5 programs whose next study reaches primary completion

  1. Candidate UTI vaccine HTD formulation 2phase 2 · May 3 · NCT06702449
  2. Candidate UTI vaccine low dose formulation 1phase 2 · May 3 · NCT06702449
  3. VH4770359phase 1 · May 5 · NCT07525544
  4. gepotidacinphase 3 · May 17 · NCT07645235
  5. GSK4771261phase 1 · May 20 · NCT07600450

GlaxoSmithKline, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Bevacizumabphase 2 · Jun 21 · NCT06796907
  2. belimumabapproved, new study · Jun 29 · NCT06411249
  3. Low dose Strep A Alumphase 1 · Jun 29 · NCT07085702
  4. Low dose Strep A AS37phase 1 · Jun 29 · NCT07085702

GlaxoSmithKline, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mRNA Seasonal Flu vaccinephase 3 · Jul 9 · NCT07851246

GlaxoSmithKline, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. belantamabphase 2 · Aug 5 · NCT07742527
  2. shingrixapproved, new study · Aug 23 · NCT05371080

GlaxoSmithKline, Sep ’27: 1 program whose next study reaches primary completion

  1. mocertatug rezetecanphase 3 · Sep 22 · NCT06431594

GlaxoSmithKline, Oct ’27: 4 programs whose next study reaches primary completion

  1. GSK3772701phase 2 · Oct 8 · NCT07545681
  2. efimosfermin alfaphase 3 · Oct 13 · NCT07358546
  3. Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514phase 2 · Oct 26 · NCT06990880
  4. VH4524184phase 2 · Oct 28 · NCT07202546
Gilead Sciences10 readouts · 2 phase 3·

Gilead Sciences, Dec ’26: 2 programs whose next study reaches primary completion

  1. anitocabtagene autoleucelphase 3 · Dec 0 · NCT05396885
  2. sacituzumab govitecanapproved, new study · Dec 0 · NCT04617522
··

Gilead Sciences, Mar ’27: 4 programs whose next study reaches primary completion

  1. domvanalimabphase 3 · Mar 0 · NCT06727565
  2. GS-0151phase 1 · Mar 0 · NCT06902519
  3. lenacapavirapproved, new study · Mar 0 · NCT06749054
  4. Optimized Background Regimen (OBR)phase 3 · Mar 0 · NCT06749054
··

Gilead Sciences, Jun ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. Emtricitabineapproved, new study · Jun 0 · NCT06337032
  2. tenofovir alafenamideapproved, new study · Jun 0 · NCT06337032
·

Gilead Sciences, Aug ’27: 2 programs whose next study reaches primary completion

  1. bictegravirapproved, new study · Aug 0 · NCT07645287
  2. GS-3242phase 3 · Aug 0 · NCT07645287
··
Pfizer37 readouts · 10 phase 3

Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rimegepantapproved, new study · Nov 29 · NCT06641466

Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. ritlecitinibphase 3 · Dec 2 · NCT07029711
  2. vepdegestrantphase 3 · Dec 4 · NCT07231991
  3. VLA15phase 3 · Dec 4 · NCT07500506
  4. prifetrastatphase 3 · Dec 8 · NCT07721402
  5. disitamab vedotinphase 3 · Dec 11 · NCT04879329

and 3 more — sign in to see them all

Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08653945phase 2 · Jan 13 · NCT07725809
  2. abrysvophase 3 · Jan 18 · NCT05035212
  3. berobenatidephase 3 · Jan 27 · NCT07508241

Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. osivelotorphase 3 · Feb 8 · NCT06507904
  2. tilrekimigphase 3 · Feb 20 · NCT07792941
  3. PF-07328948phase 2 · Feb 23 · NCT07269301
  4. atirmociclibphase 3 · Feb 26 · NCT05262400
  5. mevrometostatphase 3 · Feb 28 · NCT06551324

Pfizer, Mar ’27: 3 programs whose next study reaches primary completion

  1. PG4phase 3 · Mar 4 · NCT06524414
  2. PF-08161842phase 1 · Mar 17 · NCT07897708
  3. PF-08103402phase 1 · Mar 30 · NCT07660731

Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08642534phase 1 · Apr 21 · NCT07731139
  2. PG4 Multivalent Vaccinephase 3 · Apr 26 · NCT07794748

Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abrocitinibphase 3 · May 2 · NCT06807268
  2. marstacimabphase 3 · May 5 · NCT06703606

Pfizer, Jun ’27: 3 programs whose next study reaches primary completion

  1. PF-07832837phase 1 · Jun 2 · NCT06564389
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3 · Jun 10 · NCT07023081
  3. sigvotatug vedotinphase 3 · Jun 16 · NCT04389632
·

Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. elranatamabapproved, new study · Aug 4 · NCT05317416
  2. zavegepantphase 3 · Aug 12 · NCT06995729
  3. claturafenibphase 1 · Aug 31 · NCT05355701
  4. polfurmetinibphase 1 · Aug 31 · NCT05538130

Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. PF-08065010phase 1 · Sep 1 · NCT07235163
  2. ibuzatrelvirphase 3 · Sep 28 · NCT07013474
  3. remdesivirphase 3 · Sep 28 · NCT07013474

Pfizer, Oct ’27: 3 programs whose next study reaches primary completion

  1. tivunatamigphase 3 · Oct 18 · NCT07227012
  2. PA-001phase 1 · Oct 21 · NCT07086677
  3. PG4 in Buffer 1 with low dose PA-002phase 1 · Oct 21 · NCT07086677
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

GlaxoSmithKline

New programs 5

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 10

Gilead Sciences

New programs 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 6

Pfizer

New programs 6

Reached a new phase 0

None

Study stopped 3

  • PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 44 in all. A program counts in each condition its studies name most.

ConditionGlaxoSmithKlineGilead SciencesPfizer
HIV Infectionsall three · compare here

GlaxoSmithKline in HIV Infections: 14 programs

  1. fostemsavirphase 3
  2. CAB ULAphase 3
  3. dezecapavirphase 2
  4. VH4524184phase 2
  5. VH3810109phase 2

and 9 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of HIV Infections in search

Gilead Sciences in HIV Infections: 5 programs

  1. teropavimabphase 3
  2. zinlirvimabphase 3
  3. lenacapavirapproved, new study
  4. tenofovir alafenamideapproved, new study
  5. Emtricitabineapproved, new study

Their studies: Gilead Sciences’ studies of HIV Infections in search

Pfizer in HIV Infections: 1 program

  1. 13-valent pneumococcal vaccineapproved, new study

Their studies: Pfizer’s studies of HIV Infections in search

Carcinoma, Non-Small-Cell Lungall three · compare here

GlaxoSmithKline in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. risvutatug rezetecanphase 3
  2. momelotinibphase 3
  3. neladalkibphase 3
  4. feladilimabphase 3
  5. nelistotugphase 2

and 3 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Carcinoma, Non-Small-Cell Lung in search

Gilead Sciences in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. domvanalimabphase 3
  2. Topotecanphase 3
  3. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Carcinoma, Non-Small-Cell Lung in search

Pfizer in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. tivunatamigphase 3
  2. prifetrastatphase 3
  3. disitamab vedotinphase 3
  4. sigvotatug vedotinphase 3
  5. ponsegromabphase 3

and 3 more — sign in to see them all

Their studies: Pfizer’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsall three · compare here

GlaxoSmithKline in Breast Neoplasms: 3 programs

  1. nirogacestatphase 2
  2. Bevacizumabphase 2
  3. niraparibapproved, new study

Their studies: GlaxoSmithKline’s studies of Breast Neoplasms in search

Gilead Sciences in Breast Neoplasms: 4 programs

  1. amrubicinphase 3
  2. lurbinectedinphase 3
  3. trifluridine tipiracil drug combinationphase 2
  4. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Breast Neoplasms in search

Pfizer in Breast Neoplasms: 7 programs

  1. atirmociclibphase 3
  2. vepdegestrantphase 3
  3. prifetrastatphase 3
  4. disitamab vedotinphase 3
  5. tegtociclibphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Breast Neoplasms in search

Neoplasmsall three · compare here

Gilead Sciences in Neoplasms: 2 programs

  1. lurbinectedinphase 3
  2. Topotecanphase 3

Their studies: Gilead Sciences’ studies of Neoplasms in search

Pfizer in Neoplasms: 2 programs

  1. polfurmetinibphase 1
  2. tucatinibapproved, new study

Their studies: Pfizer’s studies of Neoplasms in search

Colorectal Neoplasmsall three · compare here

Gilead Sciences in Colorectal Neoplasms: 2 programs

  1. denikitugphase 2
  2. trifluridine tipiracil drug combinationphase 2

Their studies: Gilead Sciences’ studies of Colorectal Neoplasms in search

Pfizer in Colorectal Neoplasms: 4 programs

  1. tivunatamigphase 3
  2. tusamitamab sonditecanphase 1
  3. tucatinibapproved, new study
  4. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Colorectal Neoplasms in search

Small Cell Lung Carcinomaall three · compare here

GlaxoSmithKline in Small Cell Lung Carcinoma: 2 programs

  1. risvutatug rezetecanphase 3
  2. ivonescimabphase 2

Their studies: GlaxoSmithKline’s studies of Small Cell Lung Carcinoma in search

Gilead Sciences in Small Cell Lung Carcinoma: 4 programs

  1. amrubicinphase 3
  2. lurbinectedinphase 3
  3. Topotecanphase 3
  4. trifluridine tipiracil drug combinationphase 2

Their studies: Gilead Sciences’ studies of Small Cell Lung Carcinoma in search

Pfizer in Small Cell Lung Carcinoma: 3 programs

  1. tivunatamigphase 3
  2. mevrometostatphase 3
  3. tegtociclibphase 2

Their studies: Pfizer’s studies of Small Cell Lung Carcinoma in search

Ovarian Neoplasmsall three · compare here

GlaxoSmithKline in Ovarian Neoplasms: 6 programs

  1. mocertatug rezetecanphase 3
  2. nirogacestatphase 2
  3. Bevacizumabphase 2
  4. ivonescimabphase 2
  5. dostarlimabapproved, new study

and 1 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Ovarian Neoplasms in search

Gilead Sciences in Ovarian Neoplasms: 1 program

  1. Topotecanphase 3

Their studies: Gilead Sciences’ studies of Ovarian Neoplasms in search

Pfizer in Ovarian Neoplasms: 1 program

  1. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Ovarian Neoplasms in search

Respiratory Syncytial Virus Infectionsall three · compare here

GlaxoSmithKline in Respiratory Syncytial Virus Infections: 5 programs

  1. arexvyphase 3
  2. Adjuvanted RSVPreF3 vaccinephase 2
  3. hMPV_Y low dose vaccinephase 2
  4. RSV/hMPV_V low dose vaccinephase 2
  5. shingrixapproved, new study

Their studies: GlaxoSmithKline’s studies of Respiratory Syncytial Virus Infections in search

Gilead Sciences in Respiratory Syncytial Virus Infections: 1 program

  1. obeldesivirphase 3

Their studies: Gilead Sciences’ studies of Respiratory Syncytial Virus Infections in search

Pfizer in Respiratory Syncytial Virus Infections: 2 programs

  1. abrysvophase 3
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3

Their studies: Pfizer’s studies of Respiratory Syncytial Virus Infections in search

Multiple Myelomaall three · compare here

GlaxoSmithKline in Multiple Myeloma: 5 programs

  1. belantamab mafodotinphase 3
  2. feladilimabphase 3
  3. nirogacestatphase 2
  4. belantamabphase 2
  5. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Multiple Myeloma in search

Gilead Sciences in Multiple Myeloma: 1 program

  1. anitocabtagene autoleucelphase 3

Their studies: Gilead Sciences’ studies of Multiple Myeloma in search

Pfizer in Multiple Myeloma: 1 program

  1. elranatamabapproved, new study

Their studies: Pfizer’s studies of Multiple Myeloma in search

Endometrial Neoplasmsall three · compare here

GlaxoSmithKline in Endometrial Neoplasms: 2 programs

  1. mocertatug rezetecanphase 3
  2. dostarlimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Endometrial Neoplasms in search

Gilead Sciences in Endometrial Neoplasms: 1 program

  1. Topotecanphase 3

Their studies: Gilead Sciences’ studies of Endometrial Neoplasms in search

Pfizer in Endometrial Neoplasms: 1 program

  1. tivunatamigphase 3

Their studies: Pfizer’s studies of Endometrial Neoplasms in search

Squamous Cell Carcinoma of Head and Neckall three · compare here

GlaxoSmithKline in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. feladilimabphase 3
  2. nelistotugphase 2

Their studies: GlaxoSmithKline’s studies of Squamous Cell Carcinoma of Head and Neck in search

Gilead Sciences in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. domvanalimabphase 3

Their studies: Gilead Sciences’ studies of Squamous Cell Carcinoma of Head and Neck in search

Pfizer in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. Alpha V Beta 8 Antagonist PF-06940434phase 1

Their studies: Pfizer’s studies of Squamous Cell Carcinoma of Head and Neck in search

Arthritis, Rheumatoidall three · compare here

GlaxoSmithKline in Arthritis, Rheumatoid: 1 program

  1. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Arthritis, Rheumatoid in search

Gilead Sciences in Arthritis, Rheumatoid: 1 program

  1. GS-0151phase 1

Their studies: Gilead Sciences’ studies of Arthritis, Rheumatoid in search

Pfizer in Arthritis, Rheumatoid: 1 program

  1. ritlecitinibphase 3

Their studies: Pfizer’s studies of Arthritis, Rheumatoid in search

Neoplasm Metastasisall three · compare here

GlaxoSmithKline in Neoplasm Metastasis: 1 program

  1. neladalkibphase 3

Their studies: GlaxoSmithKline’s studies of Neoplasm Metastasis in search

Gilead Sciences in Neoplasm Metastasis: 1 program

  1. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Neoplasm Metastasis in search

Pfizer in Neoplasm Metastasis: 1 program

  1. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Neoplasm Metastasis in search

Triple Negative Breast Neoplasmsall three · compare here

GlaxoSmithKline in Triple Negative Breast Neoplasms: 1 program

  1. ivonescimabphase 2

Their studies: GlaxoSmithKline’s studies of Triple Negative Breast Neoplasms in search

Gilead Sciences in Triple Negative Breast Neoplasms: 1 program

  1. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Triple Negative Breast Neoplasms in search

Pfizer in Triple Negative Breast Neoplasms: 1 program

  1. KAT6/KAT7 Inhibitor PF-08032562phase 1

Their studies: Pfizer’s studies of Triple Negative Breast Neoplasms in search

Asthma2 of 3 · compare here

GlaxoSmithKline in Asthma: 6 programs

  1. felcorekibartphase 3
  2. norfluranephase 3
  3. HFA-152aphase 3
  4. ozureprubartphase 2
  5. HFA-152A propellantphase 1

and 1 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Asthma in search

–

Pfizer in Asthma: 3 programs

  1. tilrekimigphase 3
  2. zavegepantphase 3
  3. PF-08103402phase 1

Their studies: Pfizer’s studies of Asthma in search

Dermatitis, Atopic2 of 3 · compare here

GlaxoSmithKline in Dermatitis, Atopic: 2 programs

  1. camlipixantphase 3
  2. aletekitugphase 2

Their studies: GlaxoSmithKline’s studies of Dermatitis, Atopic in search

–

Pfizer in Dermatitis, Atopic: 7 programs

  1. tilrekimigphase 3
  2. abrocitinibphase 3
  3. etrasimodphase 3
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Dermatitis, Atopic in search

Obesity2 of 3 · compare here

GlaxoSmithKline in Obesity: 1 program

  1. efimosfermin alfaphase 3

Their studies: GlaxoSmithKline’s studies of Obesity in search

–

Pfizer in Obesity: 7 programs

  1. berobenatidephase 3
  2. PF-08653945phase 2
  3. danuglipronphase 2
  4. PF-07976016phase 2
  5. MET233phase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Obesity in search

Influenza, Human2 of 3 · compare here–

Pfizer in Influenza, Human: 3 programs

  1. abrysvophase 3
  2. qIRVphase 1
  3. 13-valent pneumococcal vaccineapproved, new study

Their studies: Pfizer’s studies of Influenza, Human in search

COVID-192 of 3 · compare here–

Gilead Sciences in COVID-19: 1 program

  1. obeldesivirphase 3

Their studies: Gilead Sciences’ studies of COVID-19 in search

Pfizer in COVID-19: 5 programs

  1. abrysvophase 3
  2. ibuzatrelvirphase 3
  3. zavegepantphase 3
  4. remdesivirphase 3
  5. PA-001phase 1

Their studies: Pfizer’s studies of COVID-19 in search

Lupus Erythematosus, Systemic2 of 3 · compare here

GlaxoSmithKline in Lupus Erythematosus, Systemic: 4 programs

  1. GSK5926371phase 2
  2. GSK4527363phase 1
  3. GSK4347859phase 1
  4. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Lupus Erythematosus, Systemic in search

–

Pfizer in Lupus Erythematosus, Systemic: 2 programs

  1. dazukibartphase 3
  2. PF-08154225phase 2

Their studies: Pfizer’s studies of Lupus Erythematosus, Systemic in search

Acquired Immunodeficiency Syndrome2 of 3 · compare here

GlaxoSmithKline in Acquired Immunodeficiency Syndrome: 3 programs

  1. cabotegravirapproved, new study
  2. Dolutegravirapproved, new study
  3. Lamivudineapproved, new study

Their studies: GlaxoSmithKline’s studies of Acquired Immunodeficiency Syndrome in search

Gilead Sciences in Acquired Immunodeficiency Syndrome: 2 programs

  1. tenofovir alafenamideapproved, new study
  2. Emtricitabineapproved, new study

Their studies: Gilead Sciences’ studies of Acquired Immunodeficiency Syndrome in search

–
Prostatic Neoplasms2 of 3 · compare here–

Pfizer in Prostatic Neoplasms: 1 program

  1. mevrometostatphase 3

Their studies: Pfizer’s studies of Prostatic Neoplasms in search

Colitis, Ulcerative2 of 3 · compare here

GlaxoSmithKline in Colitis, Ulcerative: 2 programs

  1. aletekitugphase 2
  2. GSK4528287phase 1

Their studies: GlaxoSmithKline’s studies of Colitis, Ulcerative in search

–

Pfizer in Colitis, Ulcerative: 2 programs

  1. etrasimodphase 3
  2. PF-07054894phase 1

Their studies: Pfizer’s studies of Colitis, Ulcerative in search

Hepatitis B2 of 3 · compare here

GlaxoSmithKline in Hepatitis B: 2 programs

  1. bepirovirsenapproved, new study
  2. Lamivudineapproved, new study

Their studies: GlaxoSmithKline’s studies of Hepatitis B in search

–
Hepatitis B, Chronic2 of 3 · compare here

GlaxoSmithKline in Hepatitis B, Chronic: 3 programs

  1. GSK-3965193phase 2
  2. bepirovirsenapproved, new study
  3. Lamivudineapproved, new study

Their studies: GlaxoSmithKline’s studies of Hepatitis B, Chronic in search

Gilead Sciences in Hepatitis B, Chronic: 1 program

  1. tenofovir alafenamideapproved, new study

Their studies: Gilead Sciences’ studies of Hepatitis B, Chronic in search

–
Liver Cirrhosis, Biliary2 of 3 · compare here

GlaxoSmithKline in Liver Cirrhosis, Biliary: 1 program

  1. linerixibatphase 3

Their studies: GlaxoSmithKline’s studies of Liver Cirrhosis, Biliary in search

Gilead Sciences in Liver Cirrhosis, Biliary: 3 programs

  1. seladelparphase 3
  2. cilofexorphase 3
  3. PTM Cilofexor Dose Aphase 2

Their studies: Gilead Sciences’ studies of Liver Cirrhosis, Biliary in search

–
Non-alcoholic Fatty Liver Disease2 of 3 · compare here

GlaxoSmithKline in Non-alcoholic Fatty Liver Disease: 2 programs

  1. efimosfermin alfaphase 3
  2. gatuzosiranphase 2

Their studies: GlaxoSmithKline’s studies of Non-alcoholic Fatty Liver Disease in search

Gilead Sciences in Non-alcoholic Fatty Liver Disease: 2 programs

  1. seladelparphase 3
  2. cilofexorphase 3

Their studies: Gilead Sciences’ studies of Non-alcoholic Fatty Liver Disease in search

–
Pulmonary Disease, Chronic Obstructive2 of 3 · compare here

GlaxoSmithKline in Pulmonary Disease, Chronic Obstructive: 3 programs

  1. felcorekibartphase 3
  2. GSK3862995Bphase 2
  3. depemokimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Pulmonary Disease, Chronic Obstructive in search

–

Pfizer in Pulmonary Disease, Chronic Obstructive: 1 program

  1. tilrekimigphase 3

Their studies: Pfizer’s studies of Pulmonary Disease, Chronic Obstructive in search

Streptococcal Infections2 of 3 · compare here

GlaxoSmithKline in Streptococcal Infections: 2 programs

  1. Low dose Strep A Alumphase 1
  2. Low dose Strep A AS37phase 1

Their studies: GlaxoSmithKline’s studies of Streptococcal Infections in search

–
Adenocarcinoma Of Esophagus2 of 3 · compare here–

Gilead Sciences in Adenocarcinoma Of Esophagus: 2 programs

  1. domvanalimabphase 3
  2. denikitugphase 2

Their studies: Gilead Sciences’ studies of Adenocarcinoma Of Esophagus in search

Pfizer in Adenocarcinoma Of Esophagus: 1 program

  1. tucatinibapproved, new study

Their studies: Pfizer’s studies of Adenocarcinoma Of Esophagus in search

Diabetes Mellitus, Type 22 of 3 · compare here

GlaxoSmithKline in Diabetes Mellitus, Type 2: 1 program

  1. linerixibatphase 3

Their studies: GlaxoSmithKline’s studies of Diabetes Mellitus, Type 2 in search

–

Pfizer in Diabetes Mellitus, Type 2: 2 programs

  1. berobenatidephase 3
  2. danuglipronphase 2

Their studies: Pfizer’s studies of Diabetes Mellitus, Type 2 in search

Diphtheria2 of 3 · compare here

GlaxoSmithKline in Diphtheria: 2 programs

  1. Pentetic Acidphase 3
  2. dTpa vaccinephase 3

Their studies: GlaxoSmithKline’s studies of Diphtheria in search

–
Nasal Polyps2 of 3 · compare here

GlaxoSmithKline in Nasal Polyps: 2 programs

  1. felcorekibartphase 3
  2. depemokimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Nasal Polyps in search

–

Pfizer in Nasal Polyps: 1 program

  1. rimegepantapproved, new study

Their studies: Pfizer’s studies of Nasal Polyps in search

Stomach Neoplasms2 of 3 · compare here–

Gilead Sciences in Stomach Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationphase 2

Their studies: Gilead Sciences’ studies of Stomach Neoplasms in search

Pfizer in Stomach Neoplasms: 2 programs

  1. tivunatamigphase 3
  2. disitamab vedotinphase 3

Their studies: Pfizer’s studies of Stomach Neoplasms in search

Alzheimer Disease2 of 3 · compare here

GlaxoSmithKline in Alzheimer Disease: 1 program

  1. nivisnebartphase 2

Their studies: GlaxoSmithKline’s studies of Alzheimer Disease in search

–

Pfizer in Alzheimer Disease: 1 program

  1. PF-08161842phase 1

Their studies: Pfizer’s studies of Alzheimer Disease in search

Amyloidosis2 of 3 · compare here

GlaxoSmithKline in Amyloidosis: 1 program

  1. belantamab mafodotinphase 3

Their studies: GlaxoSmithKline’s studies of Amyloidosis in search

–

Pfizer in Amyloidosis: 1 program

  1. tafamidisapproved, new study

Their studies: Pfizer’s studies of Amyloidosis in search

Anemia, Sickle Cell2 of 3 · compare here

GlaxoSmithKline in Anemia, Sickle Cell: 1 program

  1. 4CMenB vaccineapproved, new study

Their studies: GlaxoSmithKline’s studies of Anemia, Sickle Cell in search

–

Pfizer in Anemia, Sickle Cell: 1 program

  1. osivelotorphase 3

Their studies: Pfizer’s studies of Anemia, Sickle Cell in search

Carcinoma, Transitional Cell2 of 3 · compare here–

Gilead Sciences in Carcinoma, Transitional Cell: 1 program

  1. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Carcinoma, Transitional Cell in search

Pfizer in Carcinoma, Transitional Cell: 1 program

  1. disitamab vedotinphase 3

Their studies: Pfizer’s studies of Carcinoma, Transitional Cell in search

Chronic Urticaria2 of 3 · compare here

GlaxoSmithKline in Chronic Urticaria: 1 program

  1. ozureprubartphase 2

Their studies: GlaxoSmithKline’s studies of Chronic Urticaria in search

–

Pfizer in Chronic Urticaria: 1 program

  1. ritlecitinibphase 3

Their studies: Pfizer’s studies of Chronic Urticaria in search

Diabetes Mellitus2 of 3 · compare here

GlaxoSmithKline in Diabetes Mellitus: 1 program

  1. aletekitugphase 2

Their studies: GlaxoSmithKline’s studies of Diabetes Mellitus in search

–

Pfizer in Diabetes Mellitus: 1 program

  1. danuglipronphase 2

Their studies: Pfizer’s studies of Diabetes Mellitus in search

Inflammatory Bowel Diseases2 of 3 · compare here

GlaxoSmithKline in Inflammatory Bowel Diseases: 1 program

  1. aletekitugphase 2

Their studies: GlaxoSmithKline’s studies of Inflammatory Bowel Diseases in search

–

Pfizer in Inflammatory Bowel Diseases: 1 program

  1. PF-07261271phase 1

Their studies: Pfizer’s studies of Inflammatory Bowel Diseases in search

Kidney Diseases2 of 3 · compare here

GlaxoSmithKline in Kidney Diseases: 1 program

  1. GSK4771261phase 1

Their studies: GlaxoSmithKline’s studies of Kidney Diseases in search

Gilead Sciences in Kidney Diseases: 1 program

  1. trifluridine tipiracil drug combinationphase 2

Their studies: Gilead Sciences’ studies of Kidney Diseases in search

–
Meningococcal Infections2 of 3 · compare here

GlaxoSmithKline in Meningococcal Infections: 1 program

  1. 4CMenB vaccineapproved, new study

Their studies: GlaxoSmithKline’s studies of Meningococcal Infections in search

–
Respiratory Tract Infections2 of 3 · compare here

GlaxoSmithKline in Respiratory Tract Infections: 1 program

  1. gepotidacinphase 3

Their studies: GlaxoSmithKline’s studies of Respiratory Tract Infections in search

–

Pfizer in Respiratory Tract Infections: 1 program

  1. abrysvophase 3

Their studies: Pfizer’s studies of Respiratory Tract Infections in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: GlaxoSmithKline 65 of 88 · Gilead Sciences 16 of 32 · Pfizer 67 of 91 programs (44 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (GlaxoSmithKline: 17, Pfizer: 9).